Taxus Cardium Pharmaceuticals Group Inc
Save
6.49K
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications.

Similar securities

Based on sector and market capitalization

Report issue